Yep, definitive study results will be released in January, with FDA taking up to 6months after this to provide a response for approval.
With approval I think there will be an influx of other neurodegenerate groups wanting to trial ATH434 on their disorders, so very big benefit of opening a can off worms outside of MSA/parkinsons.
Ann: Alterity to Present at Hidden Gems in Life Sciences Webinar, page-22
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $5.491K | 1.520M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 50987030 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126437200 | 27 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |